Two studies of the new HER2 selective tyrosine kinase inhibitor ONT-380 showed the drug has promising activity in HER2-positive breast cancer and especially in patients with central nervous system metastases.
T-DM1 improved survival in women with HER2-positive breast cancer, even after treatment with two or more other HER2-targeted therapies including trastuzumab and lapatinib.
The addition of carboplatin to a neoadjuvant chemotherapy regimen resulted in improvements in disease-free survival for women with triple-negative breast cancer.
Women with advanced endocrine-resistant breast cancer who had PIK3CA mutations in their circulating tumor DNA had an almost 4-month progression-free survival improvement when adding the PIK3CA inhibitor buparlisib to fulvestrant.
A preclinical study looking at ER-positive breast cancer indicated that tamoxifen response was improved by reducing levels of the enzyme APOBEC3B and worsened by increasing levels of the enzyme.
Women with early-stage breast cancer treated with breast-conserving therapy had significantly improved 10-year overall survival compared with women who underwent mastectomy without radiation therapy.
Among local treatment options for early breast cancer patients, mastectomy plus reconstruction has the highest rate of complications and is highest in cost.
Patients with breast cancer who still had residual disease after undergoing neoadjuvant chemotherapy and surgery had improved survival outcomes with the addition of adjuvant capecitabine to standard treatment.
The addition of denosumab to adjuvant hormonal therapy in postmenopausal breast cancer patients improves disease-free survival compared with placebo.
Premenopausal women with luminal A breast tumors received no benefit from treatment with adjuvant chemotherapy.